Abstract 355P
Background
In Australia, 58% of cancer diagnoses and 76% of cancer mortality is in patients aged >65. Comorbidity increases with age, and both factors affect cancer treatment choices, initiation and outcomes, and health related quality of life (HRQoL). Rurality also impacts these experiences, however despite emerging evidence, rural geriatric oncology populations are underrepresented in available studies. This study therefore aims to determine the prevalence of physical comorbidities among this cohort, and to study the relationship between comorbidity, rurality, treatment process and outcomes, and HRQoL.
Methods
The study includes patients aged >65, with any solid tumour diagnosis, attending a regional cancer centre. Quantitative data was obtained using validated tools to examine HRQoL, comorbidities, and clinical parameters, with analysis of predictor variables to quantity association with comorbidity and rurality. Qualitative data was obtained via focus groups with patient, caregiver and health professional cohorts, with thematic analysis undertaken using iterative coding.
Results
Qualitative data highlighted factors influencing diagnosis and treatment, including: difficulty/cost of travel; and other impacts of living in a regional location. Diagnosis delay/complication and emotional aspects were identified as key to cancer experiences, and in HRQoL. Preliminary analysis of quantitative data collected to date (n=110) complements this, with 57% of patients classified as living in outer regional Australia, and 24% as inner regional. Around 30% had at least one comorbidity. A significant relationship does appear between rurality, comorbidities, and HRQoL. The relationship with treatment outcomes is less clear.
Conclusions
Preliminary analysis identifies several key challenges to treatment commencement and completion, including financial, logistical and emotional issues. Statistical analysis further indicates that both rurality and comorbidities may negatively impact HRQoL, and treatment commencement/completion. Data collection and analysis is ongoing to end 2020.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hunter New England Local Health District - Tamworth Rural Referral Hospital.
Funding
Tamworth Hospital, Hunter New England Local Health District.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session